Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization

• Главные авторы: Kanta Hori (Автор), Shuhei Yamada (Автор), Kenji Murata (Автор), Haruka Miyata (Автор), Yuka Mizue (Автор), Aiko Murai (Автор), Tomoyuki Minowa (Автор), Kenta Sasaki (Автор), Naoki Shijubou (Автор), Terufumi Kubo (Автор), Rena Morita (Автор), Serina Tokita (Автор), Takayuki Kanaseki (Автор), Tomohide Tsukahara (Автор), Takashige Abe (Автор), Nobuo Shinohara (Автор), Yoshihiko Hirohashi (Автор), Toshihiko Torigoe (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Adoptive T cell therapy, using T cell receptor-engineered T (TCR-T) cells and chimeric antigen receptor T (CAR-T) cells, is a potent immunotherapy option. Bladder cancer is a prevalent urological malignancy, particularly in cases of muscle invasion and metastasis, for which systemic therapy is cruci...